SCHEMBL5860697

SCHEMBL5860697

CC(=O)c1sc(Br)cc1C

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GSK3B P49841 1/20 0.42
KDM4E B2RXH2 4/20 0.38
ALDH1A1 P00352 3/20 0.38
HPGD P15428 3/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
HTT P42858 1/20 0.38
DHODH Q02127 3/20 0.35
ALOX15 P16050 1/20 0.34
KMT2A Q03164 7/20 0.33
MEN1 O00255 4/20 0.33
RXFP1 Q9HBX9 2/20 0.33
MAPT P10636 2/20 0.33
NPC1 O15118 2/20 0.33
PKM P14618 2/20 0.33
RAB9A P51151 2/20 0.33
GAA P10253 1/20 0.33
LMNA P02545 1/20 0.33
DAO P14920 1/20 0.33
CA5A P35218 1/20 0.33
GPR35 Q9HC97 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL364130 0.83 GPR35 (0.44) GSK3BKDM4EALDH1A1HPGDKMT2A
SCHEMBL102004 0.82 ALDH1A1 (0.40) KDM4EALDH1A1HPGDSMN1; SMN2HTT
SCHEMBL31073398 0.81 GSK3B (0.41) GSK3BKDM4EALDH1A1ALOX15KMT2A
SCHEMBL3230443 0.80 GSK3B (0.59) GSK3BKDM4EALDH1A1HPGDSMN1; SMN2
SCHEMBL28384356 0.78 GSK3B (0.42) GSK3BKDM4EALDH1A1HPGDSMN1; SMN2
SCHEMBL27602779 0.78 GSK3B (0.47) GSK3BKDM4EALDH1A1HPGDSMN1; SMN2
SCHEMBL2730725 0.78 MAPT (0.44) GSK3BKDM4EALDH1A1HPGDSMN1; SMN2
SCHEMBL15960083 0.77 MAPT (0.51) GSK3BKDM4EALDH1A1HPGDSMN1; SMN2
SCHEMBL13277701 0.77 GSK3B (0.41) GSK3BKDM4EALDH1A1HPGDSMN1; SMN2
SCHEMBL28378935 0.77 GSK3B (0.41) GSK3BKDM4EALDH1A1HPGDSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12552757-B2 NRF2-activating compound SENJU PHARMACEUTICAL CO., LTD. (JP) 2026-02-17 US disclosed
US-20240132519-A1 NRF2-ACTIVATING COMPOUND SENJU PHARMACEUTICAL CO., LTD. (JP) 2024-04-25 US disclosed
EP-4273145-A1 NRF2-ACTIVATING COMPOUND Senju Pharmaceutical Co., Ltd. (JP) 2023-11-08 EP disclosed
CN-116669744-A Nrf2 activating compounds 千寿制药株式会社 2023-08-29 CN disclosed
US-20230024995-A1 NRF2-ACTIVATING COMPOUND SENJU PHARMACEUTICAL CO., LTD. (JP) 2023-01-26 US disclosed
US-20230024995-A1 NRF2-ACTIVATING COMPOUND SENJU PHARMACEUTICAL CO., LTD. (JP) 2023-01-26 US disclosed
WO-2022145459-A1 NRF2-ACTIVATING COMPOUND 千寿製薬株式会社 2022-07-07 WO disclosed
WO-2022145459-A1 NRF2-ACTIVATING COMPOUND 千寿製薬株式会社 2022-07-07 WO disclosed
EP-3998262-A1 NRF2-ACTIVATING COMPOUND Senju Pharmaceutical Co., Ltd. (JP) 2022-05-18 EP disclosed
EP-3998262-A1 NRF2-ACTIVATING COMPOUND Senju Pharmaceutical Co., Ltd. (JP) 2022-05-18 EP disclosed
CN-114080389-A Nrf2 activating compound 千寿制药株式会社 2022-02-22 CN disclosed
WO-2021002473-A1 NRF2-ACTIVATING COMPOUND 千寿製薬株式会社 2021-01-07 WO disclosed
US-7091237-B2 Furan and thiophene derivatives that activate human peroxisome proliferator activated receptors SMITHKLINE BEECHAM CORPORATION (US) 2006-08-15 US disclosed
EP-1392674-B1 FURAN AND THIOPHENE DERIVATIVES THAT ACTIVATE HUMAN PEROXISOME PROLIFERATOR ACTIVATED RECEPTORS SMITHKLINE BEECHAM CORP (US) 2005-08-10 EP disclosed
US-20040157890-A1 Furan and thiophene derivatives that activate human peroxisome profilerator activated receptors GLAXO GROUP LIMITED (GB) 2004-08-12 US disclosed
EP-1392674-A1 FURAN AND THIOPHENE DERIVATIVES THAT ACTIVATE HUMAN PEROXISOME PROLIFERATOR ACTIVATED RECEPTORS GLAXO GROUP LIMITED (GB) 2004-03-03 EP disclosed
WO-2002092590-A1 FURAN AND THIOPHENE DERIVATIVES THAT ACTIVATE HUMAN PEROXISOME PROLIFERATOR ACTIVATED RECEPTORS GLAXO GROUP LIMITED (GB) 2002-11-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230024995-A1 NRF2-ACTIVATING COMPOUND NFE2L2, KEAP1, NFE2 GSK3B 2223/4885KDM4E 2390/4885ALDH1A1 555/4885
US-20040157890-A1 Furan and thiophene derivatives that activate human peroxisome profilerator activated receptors PPARG, PPARD, PPARA GSK3B 4083/4885KDM4E 4485/4885ALDH1A1 1729/4885
US-12552757-B2 NRF2-activating compound NFE2L2, NFE2, KEAP1 GSK3B 1862/4885KDM4E 1987/4885ALDH1A1 790/4885
US-20240132519-A1 NRF2-ACTIVATING COMPOUND NFE2L2, KEAP1, NFE2 GSK3B 564/4885KDM4E 3587/4885ALDH1A1 756/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.